1-(4-(4-((2-chloro-5-fluoropyrimidin-4-yl)amino)-3-methoxyphenyl)piperazin-1-yl)ethanone | 1474014-16-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 1-(4-(4-((2-chloro-5-fluoropyrimidin-4-yl)amino)-3-methoxyphenyl)piperazin-1-yl)ethanone
• 英文别名: 1-[4-[4-[(2-chloro-5-fluoropyrimidin-4-yl)amino]-3-methoxyphenyl]piperazin-1-yl]ethanone
• CAS: 1474014-16-8
• 化学式: C₁₇H₁₉ClFN₅O₂
• 分子量: 379.822
• InChiKey: PUDHPNACBOBOQE-UHFFFAOYSA-N

物化性质

• 沸点：
  605.4±55.0 °C(Predicted)
• 密度：
  1.372±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  26
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  70.6
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  1-(4-(4-((2-chloro-5-fluoropyrimidin-4-yl)amino)-3-methoxyphenyl)piperazin-1-yl)ethanone 在 tris-(dibenzylideneacetone)dipalladium(0) 、 potassium carbonate 、 三乙胺 、 2-二环己基磷-2,4,6-三异丙基联苯 作用下， 以 二氯甲烷 、 叔丁醇 为溶剂， 反应 5.25h， 生成 N-(3-((4-((4-(4-acetylpiperazin-1-yl)-2-methoxyphenyl)amino)-5-fluoropyrimidin-2-yl)amino)phenyl)propionamide
  参考文献：
  名称：

  [EN] HETEROCYCLIC COMPOUNDS AND USES THEREOF
  [FR] COMPOSÉS HÉTÉROCYCLIQUES ET LEURS UTILISATIONS

  摘要：

  The present disclosure relates to pharmaceutical compounds, compositions and methods, especially as they are related to compositions and methods comprising a compound of any one of Formulas (I), (II), (III), and (IV) as further described herein. The compounds are inhibitors of protein kinases associated with cancers, and are thus useful for the treatment and/or prevention of a tumor or cancer.

  公开号：

  WO2023287783A1
• 作为产物：
  描述：

  1-(3-methoxy-4-nitrophenyl)piperazine 在 5%-palladium/activated carbon 、 potassium carbonate 、 一水合肼 、 三乙胺 作用下， 以 乙醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 4.17h， 生成 1-(4-(4-((2-chloro-5-fluoropyrimidin-4-yl)amino)-3-methoxyphenyl)piperazin-1-yl)ethanone
  参考文献：
  名称：

  [EN] HETEROCYCLIC COMPOUNDS AND USES THEREOF
  [FR] COMPOSÉS HÉTÉROCYCLIQUES ET LEURS UTILISATIONS

  摘要：

  The present disclosure relates to pharmaceutical compounds, compositions and methods, especially as they are related to compositions and methods comprising a compound of any one of Formulas (I), (II), (III), and (IV) as further described herein. The compounds are inhibitors of protein kinases associated with cancers, and are thus useful for the treatment and/or prevention of a tumor or cancer.

  公开号：

  WO2023287783A1

文献信息

• N2,N4-BIS(4-(PIPERAZINE-1-YL)PHENYL)PIRIMIDINE-2,4-DIAMINE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING CANCER
  申请人：KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY

  公开号：US20150152069A1

  公开（公告）日：2015-06-04

  Disclosed herein are a new N2,N4-bis(4-(piperazin-1-yl)phenyl)pyrimidin-2,4-diamine derivative or a pharmaceutically acceptable salt thereof and a pharmaceutical composition for the prevention or treatment of cancers containing the same as an active ingredient. The compound of the present invention has excellent inhibitory effects against the activities of anaplastic lymphoma kinase (ALK) and activated cdc42-associated kinase (ACK1) and thus can improve the therapeutic effects on the treatment of cancer cells having anaplastic lymphoma kinase fusion proteins such as EML4-ALK and NPM-ALK, and also effectively prevent the recurrence of cancers thus being useful as a pharmaceutical composition for the prevention and treatment of cancers.

  本文披露了一种新的N2,N4-双(4-(哌嗪-1-基)苯基)嘧啶-2,4-二胺衍生物或其药用可接受的盐，以及一种包含该衍生物作为活性成分的用于预防或治疗癌症的药物组合物。本发明的化合物对间变性淋巴瘤激酶（ALK）和活化cdc42相关激酶（ACK1）的活性具有出色的抑制作用，从而可以改善对具有间变性淋巴瘤激酶融合蛋白（如EML4-ALK和NPM-ALK）的癌细胞的治疗效果，并有效预防癌症的复发，因此可作为一种用于预防和治疗癌症的药物组合物而具有实用性。
• Novel 2,4-dianilino-5-fluoropyrimidine derivatives possessing ALK inhibitory activities
  作者：Jeong In Yun、Eun Hye Yang、Muhammad Latif、Hyeon Ji Lee、Kwangho Lee、Chang-Soo Yun、Chi Hoon Park、Chong Ock Lee、Chong Hak Chae、Sung Yun Cho、Hee Jung Jung、Pilho Kim、Sang Un Choi、Hyoung Rae Kim

  DOI：10.1007/s12272-013-0247-7

  日期：2014.7

  A new series of 2,4-dianilino-5-fluoropyrimidine derivatives were designed and synthesized and their anaplastic lymphoma kinase (ALK) inhibitory activities were evaluated by biochemical and cell-based assays in order to discover a new ALK inhibitor. Most compounds synthesized showed good inhibitory activities against ALK and good cytotoxic activities in H3122 cell line. The best compound 6f showed good activity against wild-type ALK along with crizotinib-resistant mutant ALK, and it showed 6 times better activity in cell-based assay than crizotinib. Some SAR studies were performed by the comparisons of the activities between 6 and the designed-synthesized compounds.

  为了发现一种新的 ALK 抑制剂，我们设计并合成了一系列新的 2,4-二苯胺基-5-氟嘧啶衍生物，并通过生化和细胞试验评估了它们对无性淋巴瘤激酶（ALK）的抑制活性。合成的大多数化合物对 ALK 具有良好的抑制活性，并对 H3122 细胞株具有良好的细胞毒性。最好的化合物 6f 对野生型 ALK 和克唑替尼耐药突变型 ALK 都表现出了良好的活性，在基于细胞的检测中，它的活性是克唑替尼的 6 倍。通过比较 6 和设计合成的化合物的活性，进行了一些 SAR 研究。
• N2,N4-BIS(4-(PIPERAZINE-1-YL)PHENYL)PIRIMIDINE-2,4-DIAMINE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND COMPOSITION CONTAINING THE SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING CANCER
  申请人：Korea Research Institute of Chemical Technology

  公开号：EP2883875B1

  公开（公告）日：2016-12-28
• New Pyrimidine Derivatives possessing ALK Inhibitory Activities
  作者：Eun Hye Yang、Jeong In Yun、Muhammad Latif、Hyeon Ji Lee、Chang-Soo Yun、Kwangho Lee、Chi Hoon Park、Sung Yun Cho、Hee Jung Jung、Pilho Kim、Jae Du Ha、Hyoung Rae Kim

  DOI：10.5012/bkcs.2013.34.10.3129

  日期：2013.10.20
• US9199944B2
  申请人：——

  公开号：US9199944B2

  公开（公告）日：2015-12-01